Dr. Marcello DiMare has been named to the new position of senior director, chemistry development within Aptuit’s API business line. This follows the company’s recent acquisition of EaglePicher Pharmaceutical Services, expanding its API and drug development capabilities to include chemical process development, clinical trial supply of API and post-launch commercial drug manufacture.

Dr. DiMare brings 25 years of experience gained through his work at a variety of pharmaceutical companies in the U.S. and Europe. Dr. DiMare most recently served as senior director of business development at Dr. Reddy’s Laboratories and held senior positions at Rhodia ChiRex and ChiRex, Inc.

“Marcello offers a remarkable mix of expertise in chemical development, as well as the proven management know-how necessary for us to continue to expand our API and drug substance manufacturing capabilities and fulfill our vision of providing customers with truly integrated, full-service drug development solutions,” said Michael J. Butler Ph.D., president, scientific operations at Aptuit. “Throughout his career, Marcello has demonstrated his ability to assess opportunities from both a scientific as well as business perspective.”

Dr. DiMare will concentrate on building Aptuit’s process development and custom syntheses business, focused on post-discovery preclinical and clinical trial custom API synthesis and supply. He will also build and extend the radiolabeling expertise acquired from EaglePicher. Also, in Phase I of Aptuit’s Kansas City build-out, Dr. DiMare will recruit 12 to 18 chemists to fill-out the company’s newly-designed GLP laboratories, and will consolidate Aptuit and EaglePicher’s capabilities.

“Aptuit is realizing its mission to offer market-leading API drug substance manufacturing capabilities and this is an exciting opportunity for me to lend my experience and skill-set to identify and secure resources necessary to provide customers with state-of-the-art API technologies and innovative solutions to address their unique challenges,” noted Dr. DiMare.